Acalabrutinib

阿可替尼

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameAcalabrutinib
Drug Alias NameAcalabrutinibum阿卡卢替尼阿卡替尼Acalabrutinib Maleate马来酸阿可替尼 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Central Nervous System LymphomaRichter's Syndrome +[32] 
Global Approved IndicationsLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid
Approved Indications in ChinaLymphoma, Mantle-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2017/10/31
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca PlcAcerta Pharma Llc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteAstrazeneca SaSwiss Cancer Institute +[12] 
Inactive CompaniesWeill Medical College of Cornell UniversityThe First Affiliated Hospital With Nanjing Medical UniversityThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsCentral Nervous System LymphomaRichter's SyndromeDrug-Related Side Effects and Adverse Reactions +[23] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Hepatic InsufficiencyArthritis, Rheumatoid +[9] 

Other Information

ATC CodeL01EL02
Related LinksWikipediaDrugBankKEGG